Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Vaccine characteristics influencing vaccination acceptance by demographics (N = 19,702)

From: COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries

 

Required doses of COVID-19 vaccinea

Effectiveness threshold of COVID-19 vaccineb

Adverse reactions of COVID-19 vaccinec

Duration of COVID-19 vaccine protectiond

Technology used in COVID-19 vaccinee

Producing country of COVID-19 vaccinef

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Socio demography

 Age group, years

  18–29

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

  30–39

1.63 (1.41–1.87)***

0.72 (0.63–0.83)***

0.58 (0.49–0.68)***

1.01 (0.88–1.16)

1.60 (1.03–2.47)

0.99 (0.85–1.14)

  40–49

1.89 (1.61–2.22)***

0.53 (0.45–0.62)***

0.45 (0.38–0.54)***

0.99 (0.85–1.16)

2.29 (1.4–3.75)***

0.91 (0.78–1.06)

  50–59

1.91 (1.59–2.28)***

0.61 (0.51–0.73)***

0.41 (0.34–0.51)***

0.98 (0.82–1.17)

2.55 (1.52–4.29)***

0.81 (0.75–1.06)

  60 and above

1.14 (0.93–1.387)

0.69 (0.56–0.84)***

0.41 (0.33–0.51)***

1.01 (0.84–1.22)

1.26 (0.71–2.26)*

0.84 (0.69–1.02)

 Gender

  Male

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

  Female

0.86 (0.78–0.96)**

1.12 (1.01–1.25)*

1.09 (0.97–1.23)

1.07 (0.96–1.19)

1.31 (1.08–1.57)***

1.08 (0.97–1.21)

 Highest education level

  Secondary school and below

1.54 (1.27–1.85)**

1.37 (1.12–1.68)***

1.04 (0.83–1.31)

1.33 (1.10–1.61)***

0.79 (0.45–1.38)

1.08 (0.90–1.30)

  Certificate/A-Level/Diploma

1.42 (1.21–1.66)***

0.78 (0.66–0.91)***

0.58 (0.49–0.69)***

0.91 (0.77–1.06)

1.00 (0.64–1.59)

1.04 (0.89–1.21)

  Bachelor degree

1.20 (1.04–1.38)***

0.99 (0.86–1.15)

0.86 (0.73–1.01)

1.04 (0.91–1.20)

0.78 (0.49–1.25)

0.84 (0.73–0.97)*

  Postgraduate degree

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Ever delayed acceptance or refuse vaccine despite availability of vaccine service

  Yes

1.71 (1.49–1.96)***

1.77 (1.52–2.07)***

1.82 (1.52–2.16)***

1.52 (1.32–1.75)***

1.284(0.783–2.107)

0.63 (0.55–0.73)***

  No

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

  1. Other gender was excluded due to small sample size
  2. a: Only accept single dose vs Do not mind, b: Only accept 90% threshold vs Do not mind, c: Only accept minor adverse reactions vs Do not mind moderate adverse reactions, d: Only accept lesser than 12 months vs Do not mind moderate adverse reactions, e: Do not accept mRNA technology vs Do not know much about mRNA technology/Do not mind, f: Only accept a vaccine that is produced by specific countries vs Producing countries of a COVID-19 vaccine is not of my concern in vaccine choice
  3. aP-value: P < 0.001; Nagelkerke R2: 0.044
  4. bP-value: P < 0.001; Nagelkerke R2: 0.044
  5. cP-value: 0.001; Nagelkerke R2: 0.066
  6. dP-value: 0.001; Nagelkerke R2: 0.013
  7. eP-value: 0.001; Nagelkerke R2: 0.013
  8. fP-value: 0.010; Nagelkerke R2: 0.014
  9. *P < 0.05, **P < <0.01, ***P < <0.001